Generative Engine Optimization for Healthcare and Life Sciences

What is generative engine optimization and how does it work for healthcare brands?

Generative engine optimization is the practice of structuring and sourcing content so that a generative engine is more likely to retrieve it, cite it and recommend what it describes. Where search engine optimisation competes for a position in a list of links, GEO competes for inclusion in a composed answer — and the unit of success is not a click but a mention, a citation, or a recommendation. For a healthcare brand it works through four layers that have to be designed together: the prompts your audience actually uses, the content that answers them in a form a model can extract, the third-party sources the model trusts more than it trusts you, and the measurement that tells you whether any of it moved. The fourth layer is where most programmes fail, because there is no rank to track, and the first layer is where most of them never start, because teams reuse their keyword list instead of modelling how people actually ask.

Where the term comes from

GEO is not an agency coinage, which matters because a great deal of what is sold under the name has no research behind it. The term was introduced in a paper presented at KDD '24, the 30th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, in Barcelona in August 2024, by Pranjal Aggarwal of IIT Delhi with Vishvak Murahari, Karthik Narasimhan and Ameet Deshpande of Princeton and two independent researchers, Tanmay Rajpurohit and Ashwin Kalyan.

The authors described GEO as a black-box optimisation framework — a way of improving content's visibility in generative responses without knowing the engine's internal algorithm. That framing is worth holding on to, because it sets the honest ceiling on the whole discipline. Nobody doing GEO knows the ranking function. Everyone doing GEO is inferring it from outputs. Any vendor who implies otherwise is overselling.

GEO, SEO and AEO — what is actually different

The distinction that matters commercially is in row three. In search, the reader eventually sees your words. In a generative answer, they may never see your words at all — they see a summary that your content influenced. For a regulated brand that is a governance question as much as a marketing one, because you are now accountable for a communication you did not write, assembled from material you did. That problem gets its own treatment later in this guide and a full page of its own in the medical affairs and AI misinformation analysis in this cluster.

What the published research actually found

The GEO paper built a benchmark called GEO-BENCH: 10,000 queries split into 8,000 training, 1,000 validation and 1,000 test, drawn from nine sources including MS MARCO, Natural Questions, ELI5 and queries generated by GPT-4. The queries were tagged across 25 domains and 9 query types, and were roughly 80% informational with the remainder split between transactional and navigational. Each query was paired with the cleaned text of the top five Google results.

Two visibility metrics were defined. Position-adjusted word count measures how much of the response text is attributable to a given citation, weighting each sentence by an exponential decay based on where it sits in the answer — an early sentence counts for more than a late one. Subjective impression is a model-scored measure across seven sub-dimensions including relevance, influence, uniqueness and the likelihood that a user would click the citation. Both are reported as relative change against an unoptimised baseline.

Nine optimisation methods were tested. These are the results.

The paper reports the best methods improving on baseline by 41% on position-adjusted word count and 28% on subjective impression, and separately reports visibility improvements of up to 37% when tested against a live generative engine rather than the benchmark alone.

Why healthcare cannot simply run the published playbook

Read the results table again with a regulatory eye and a problem appears that has not, as far as we can establish, been written about anywhere. The three highest-performing GEO methods in the published literature are adding quotations, adding statistics and citing sources. In a regulated healthcare brand, all three are controlled acts.

The pattern in that table is the thesis of this guide. Regulatory friction and GEO effectiveness are positively correlated: the more a tactic moves the needle, the more tightly healthcare controls it, and the one tactic with no controls attached is the one that does not work. A healthcare GEO programme is therefore not a content programme with a compliance review bolted on. It is a regulatory design problem that produces content as its output.

This is also why the generalist GEO advice circulating in 2026 translates so badly. It is written for categories where you can quote a happy customer, publish a performance statistic and cite the evidence that suits you. A pharmaceutical brand can do none of those three things, and a dermocosmetic brand can do only some of them, in some markets.

Why now: the demand-side evidence, and an audit of our own number

The case for investing in this channel rests on a claim about behaviour: that clinicians and patients are now routinely getting healthcare information from generative systems. That claim is widely asserted and often badly sourced, so it is worth setting out what the primary evidence actually says including where it disagrees with itself.

What two primary surveys found

The two surveys disagree on level and agree on everything that matters. 72% against 54% is a wide gap, explicable by different definitions of use, different samples and different fielding windows. But both show steep growth inside twelve months, both identify research and literature lookup as the leading clinical use case, and both put it in the mid-to-high thirties. For a commercial team the operative finding is not the headline adoption figure at all. It is that roughly a third of practising physicians are now using generative systems to summarise the evidence base in which your product sits.

The AMA survey adds one more figure worth carrying into any patient-facing discussion: 70% of physicians regard patients' use of general-purpose AI for health information as positive or neutral when used appropriately, with comfort highest for medication questions at 68%. The clinician community is not, on the whole, trying to keep patients away from this channel.

A provenance audit, applied to ourselves

This programme audits the circulating statistics in every category it writes about. It would be indefensible to exempt our own, so here is the finding.

Retiring one of your own numbers in public is a small thing that does a disproportionate amount of work. It is also, in this specific channel, self-interested: generative systems reward sources that are verifiable, and the fastest way to become unverifiable is to circulate a figure nobody can trace. The provenance discipline that makes a page trustworthy to a medical reviewer is the same discipline that makes it citable by a model.

How do I measure whether AI is recommending my healthcare brand?

You measure it with five numbers, and only one of them answers the question you actually asked. Presence tells you how often your brand appears at all. Visibility tells you how much of the answer is about you. Share of voice tells you how that compares with your competitive set. Average position tells you where in the answer you land. Recommendation rate tells you how often you are the option the engine actually puts forward — and it is routinely a fraction of presence. Because generative answers have no rank, no impression log and no referrer, all five are produced by sampling: you run a defined set of prompts, repeatedly, across multiple engines, and measure the responses. That makes a stated prompt sample and run count the minimum condition for believing any number in this category, including ours.

The five metrics

Presence is not recommendation, and the gap is the whole story

A brand can be mentioned in 68% of relevant answers and recommended in 12% of them. Those are not inconsistent numbers; they describe a specific and common commercial position — the engine knows you exist, discusses you as context, and puts someone else forward when the reader asks what to do.

In prescription categories that gap is usually widest at the Compare and Choose stages, where guideline bodies, specialist societies and large health publishers hold the ground and branded assets drop out. A presence-only report will show that brand performing well right up to the point where the decision is made.

Report the two numbers side by side, always, and trend the gap rather than either number alone. A programme that raises presence while the gap widens has bought awareness in a channel where awareness is not the constraint. The indication-level worked examples are in the prescription dermatology analysis in this cluster.

What you cannot measure, and what to say when asked

A pillar page that only lists capabilities is a brochure. These are the things this channel genuinely does not give you, and a buyer should hear them before signing anything.

That table is the single most useful thing to take into a vendor meeting. Every entry in it is a question a serious buyer should ask, and the quality of the answer separates a measurement product from a dashboard with confident numbers on it.

The journey and persona model

A blended visibility score across all prompts is almost useless, for the same reason a blended conversion rate across all hospital departments is almost useless: it averages together situations that behave completely differently. The model that makes the variation visible has two dimensions.

Cross that with persona and the picture sharpens again. The same indication produces four materially different prompt sets depending on whether the asker is a patient, a caregiver, a primary care physician or a specialist — different vocabulary, different depth, different sources cited back. A caregiver asks about managing a condition in someone else; a specialist asks about sequencing after failure of first-line therapy. One content programme cannot serve both, and a measurement that blends them cannot show you which one you are losing.

Four stages against four personas gives sixteen cells. Plotted as a heatmap, the gaps are usually obvious within an hour of looking at the first dataset — and they are almost never where the brand team expected. The construction of the prompt sets themselves is the subject of the health publisher prompt map, and the HCP-versus-patient split is developed in the dermatologist-facing versus patient-facing analysis.

Who AI actually cites in healthcare

Generative engines do not treat all sources as equivalent, and in health topics the hierarchy is steeper than in most categories. The practical consequence for a brand is uncomfortable and worth stating plainly: your product page is near the bottom of the order, and no amount of optimisation moves it to the top.

The strategic read is that a brand's route into a health answer usually runs through somebody else's domain. That is a genuine departure from search, where you could rank your own page for your own category term. In generative health answers, the realistic objective is to be the source that tiers one to four are drawing on, and to be unimpeachable on the tier-five questions that are properly yours. The full taxonomy, with observed citation frequency per tier, is being built in the how AI chooses health citations analysis — this page names the tiers; that one measures them.

The regulatory layer: what a regulated brand can and cannot do

This is the section that makes a healthcare GEO guide different from a general one, and it is the section most likely to be skipped by a marketing reader and underlined by a legal one. No regulator in any major market has issued guidance specifically on generative engine optimisation. That absence is not permission. It means the existing promotional rules apply to this surface as they apply to every other, and they were written for a world in which you controlled the words.

The United States

Verify this section before you rely on it

The US requirements above are drawn from published secondary analyses rather than from the Code of Federal Regulations directly, and at least one source consulted referenced a 2026 final rule without a citation that could be checked. Confirm each provision against the eCFR, the Federal Register and the regulator's own guidance before any of it goes into a policy document or a contract.

The structural argument survives correction to the detail. Fair balance, safety information and independent evaluation of each communication are long-standing features of US promotional regulation, and none of them becomes easier when an intermediary is summarising you. It is the specific thresholds and the status of recent rulemaking that need checking.

Other markets, briefly

The India position is worth more than a row, because it is the first direct regulatory statement on AI-generated promotional content in healthcare anywhere. It requires a visible source mark on AI-generated promotional material, prohibits synthetic patient testimonials and endorsements, and prohibits manipulating search rankings or algorithms to create a misleading impression of professional standing. Teams operating globally should expect that framing to be copied rather than remain an outlier, and designing to it now is cheaper than retrofitting to it later.

The governance position

Every regulated organisation that adopts this discipline will be asked the same question by its own legal and compliance function: who approved the thing the machine produced? There is one answer that survives scrutiny.

1. AI produces the analysis. A named human approves every action. Measurement, gap detection and prioritisation can be automated. Publication cannot. This is not a limitation of current systems; it is a design choice that should outlive them.
2. Every recommendation carries a review label and an evidence link. A prioritised action that cannot be traced to the response that generated it is not auditable, and an unauditable recommendation will not clear review.
3. Verbatim responses are retained, not just scores. When a brand team asks why the number moved, the answer is in the text the engine produced. A platform that stores only metrics cannot answer the question that matters.
4. The monitoring duty and the marketing duty are separated. Marketing owns visibility. Medical affairs owns what the engine says about safety, and the two should not share an escalation path, because one of them is a patient-safety issue.
5. Nothing is published into a promotional surface by an automated pipeline. Not a social reply, not a dynamic landing-page variant, not an FAQ answer. Approval is per asset and it is recorded.

That position costs velocity, and it is the correct trade. An organisation that cannot evidence human approval of a promotional communication has a problem that no visibility gain offsets. The broader framework we apply to this sits in our work on AI governance and ethical AI in healthcare engagement.

Three segments, three operating models

GEO is one discipline and at least three different jobs. The measurement framework and the regulatory posture are shared; almost nothing else is. These are the three segments this programme covers, and each has its own guide.

Medical publishers
 

A publisher's problem is not that AI might eventually take its audience. It is that the traffic has already gone. Visibility-index data covering mid-2024 to January 2026 shows declines of roughly 43% and 52% at two of the largest US health publishers, against a backdrop of a major December 2025 core update and a reported global publisher traffic decline of around 33%. One large health-media owner wrote off USD 54.8m on its health properties in the same period. The causal attribution to AI is a hypothesis rather than a demonstrated fact, and the revenue consequence is not in doubt.

The publisher operating model is therefore defensive and portfolio-scale. The questions are which content to optimise, which to licence, which to block, and how to measure visibility across tens of thousands of pages when you cannot track any of them individually.

Dermatology and skincare brands in AI shopping

Consumer derma is where generative answers have moved furthest from search, because the answer frequently is the purchase decision. A small published study of twelve consumer shopping prompts, run once each on two engines in October 2026, produced 24 answers in which 79 distinct brands filled 120 product slots — with two mass dermatological brands taking a disproportionate share. The sample is small and single-run, and the direction it shows is consistent with what brand teams report.

The finding with the largest operational consequence concerns where the links went. Of 87 links one engine produced, roughly 62% went to major retailers and 28% to brand websites. For most skincare brands that inverts the budget split: the retailer product page is the primary AI surface and the brand's own site is secondary.

Global dermatology companies

A dermatology group is the hardest portfolio case in healthcare, because it spans prescription therapies, over-the-counter products and dermocosmetics under one corporate parent, addressed to two audiences with entirely different vocabularies. Measurement has to work at portfolio level, which means defining a competitive set that crosses regulatory categories — something no generalist GEO tool is built to do.

It also produces a problem that appears to be unwritten anywhere else. In the observed shopping study, brands belonging to a single consumer-derma group took 21 of 70 skincare and body-care slots. For a group that also sells prescription dermatology, its own consumer brands are therefore occupying the answer surface at the stage where a patient is still deciding whether to see a doctor at all.